Cytek Biosciences, Inc. (CTKB) P/E Ratio History
Deep ValueTrading at -7.8x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2021–2022
Loading P/E history...
P/E Ratio Analysis
As of June 24, 2026, Cytek Biosciences, Inc. (CTKB) trades at a price-to-earnings ratio of -7.8x, with a stock price of $4.07 and trailing twelve-month earnings per share of $-0.57.
The current P/E is 102% below its 5-year average of 456.3x. Over the past five years, CTKB's P/E has ranged from a low of 265.3x to a high of 590.2x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.0x, CTKB trades at a 136% discount to its sector peers. The sector includes 233 companies with P/E ratios ranging from 0.0x to 196.5x.
Relative to the broader market, CTKB trades at a notable discount to the S&P 500 median P/E of 24.6x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our CTKB DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
CTKB Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
CTKB P/E vs Peers
Device suppliers, distribution, and services peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $25B | 30.3 | 7.15 | +171%Best | |
| $17B | 30.5 | - | -25% | |
| $7B | 9.7Lowest | - | +143% | |
| $23B | 33.2 | 6.41 | +0% | |
| $174B | 26.5 | 12.53 | +7% | |
| $36B | 27.7 | 1.88Best | +3% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
CTKB Historical P/E Data (2021–2022)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2022 Q4 | Dec 31 2022 | $10.21 | $0.02 | 590.2x | +29% |
| FY2022 Q1 | - | $10.78 | $0.02 | 531.0x | +16% |
| FY2021 Q4 | Dec 31 2021 | $16.32 | $0.04 | 438.7x | -4% |
| FY2021 Q3 | - | $21.41 | $0.08 | 265.3x | -42% |
Average P/E for displayed period: 456.3x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
5+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CTKB — Frequently Asked Questions
Quick answers to the most common questions about buying CTKB stock.
What is CTKB's P/E ratio?
Cytek Biosciences, Inc. (CTKB) trailing twelve-month P/E ratio is -7.8x, based on TTM diluted EPS of $-0.57. The 5-year average P/E is 456.3x and the historical range spans 265.3x to 590.2x.
Is CTKB stock overvalued or undervalued?
CTKB trades at -7.8x P/E, below its 5-year average of 456.3x. At the 0th percentile of its historical range (265.3x–590.2x), the stock is priced at a discount to its own history.
Is CTKB stock expensive?
No, CTKB is not expensive on a historical basis. The current P/E of -7.8x is below the 5-year average of 456.3x and sits at the 0th percentile of its valuation range.
What is CTKB's historical P/E range?
Over the past 5 years, CTKB's P/E ratio has ranged from 265.3x to 590.2x, with a median of 531.0x and an average of 456.3x. The current P/E of -7.8x places the stock at the 0th percentile of this range. Full historical data spans 2021–2022.
How does CTKB's P/E compare to the S&P 500?
CTKB trades at -7.8x P/E versus the S&P 500 median of 24.6x. The 132% discount to the market suggests lower growth expectations or perceived higher risk.
How does CTKB's valuation compare to Healthcare peers?
Cytek Biosciences, Inc. P/E of -7.8x compares to the Healthcare sector median of 22.0x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is CTKB's PEG ratio?
CTKB PEG ratio is N/A, based on a P/E of -7.8x and EPS growth of -1028.0%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is CTKB's earnings yield?
CTKB earnings yield is N/A, the inverse of its -7.8x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.